Iovance Biotherapeutics
IOVA
227 hedge funds and large institutions have $970M invested in Iovance Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 107 increasing their positions, 52 reducing their positions, and 31 closing their positions.
107% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $16.2M
106% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 52
32% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 31
4% more funds holding
Funds holding: 219 → 227 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.86% less ownership
Funds ownership: 90.88% → 86.01% (-4.9%)
32% less capital invested
Capital invested by funds: $1.44B → $970M (-$466M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFM
MHR Fund Management
New York
|
+$52.2M |
| 2 |
Millennium Management
New York
|
+$27.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.7M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$19.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$41.6M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$18.3M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$17.5M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$17.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$13.5M |
IOVA Hedge Fund Activity: Q3 2023 in Review
227 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2023, worth a combined $970M — down 32% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IOVA positions and 31 closed out — a net gain of 10 holders — while 107 added to existing stakes and 52 trimmed.
The largest buyer was MHR Fund Management, adding an estimated $52.2M. The largest seller was Point72 Asset Management, cutting an estimated $41.6M.
- 227 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2023, up from 219 in Q2 2023.
- Funds reported $970M of Iovance Biotherapeutics stock for Q3 2023, down 32% quarter-over-quarter.
- 41 funds opened new Iovance Biotherapeutics positions in Q3 2023 and 31 closed out, a net change of +10 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2023 was MHR Fund Management, an estimated $52.2M added.
- The largest Iovance Biotherapeutics seller in Q3 2023 was Point72 Asset Management, an estimated $41.6M sold.
Based on aggregated 13F filings for Q3 2023.